Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy

Journal of Neurosurgery

Volumn 119, Issue 5, 2013, Pages 1145-1155

  Tamura, Kaoru ^a   Aoyagi, Masaru ^a   Ando, Noboru ^a   Ogishimao, Takahiro ^a   Wakimoto, Hiroaki ^b   Yamamoto, Masaaki ^c   Ohno, Kikuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Katsuta Hospital Mito GammaHouse   (Japan)

Author keywords

Cancer stem cell; CD133; De novo glioblastoma; Immunohistochemistry; Oncology; Treatment resistance

Indexed keywords

CD133 ANTIGEN; CISPLATIN; ETOPOSIDE; KI 67 ANTIGEN; NESTIN; NIMUSTINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; GLIOMA; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PEPTIDES; RECURRENCE; YOUNG ADULT;

EID: 84887028703     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.7.JNS122417     Document Type: Article

References (35)

1. Bao S, Wu Q, McLendon R.E., Hao Y., Shi Q, Hjelmeland AB, et al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006 (Pubitemid 44949604)
2. Baumann M, Krause M, Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554, 2008 (Pubitemid 351881850)
3. Beier D, Hau P, Proescholdt M., Lohmeier A, Wischhusen J, Oefner P.J., et al.: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015, 2007 (Pubitemid 46815044)
4. Bidlingmaier S, Zhu X, Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) 86: 1025-1032, 2008
5. Calabrese C, Poppleton H, Kocak M., Hogg TL, Fuller C, Ham ner B, et al.: A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82, 2007 (Pubitemid 46054518)
6. Chang CJ, Hsu CC, Yung M.C., Chen KY, Tzao C, Wu WF, et al.: Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 380: 236-242, 2009
7. Christensen K, Schrøder HD, Kristensen BW: CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol 90: 157-170, 2008
8. Corbeil D, Röper K, Hellwig A., Tavian M, Miraglia S, Watt S.M., et al.: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520, 2000 (Pubitemid 30115186)
9. Günther H.S., Schmidt NO, Phillips H.S., Kemming D., Kharbanda S, Soriano R, et al.: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27: 2897-2909, 2008 (Pubitemid 351620450)
10. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC: PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22: 436-448, 2008 (Pubitemid 351272752)
11. Hermansen SK, Christensen KG, Jensen S.S., Kristensen BW: Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59: 391-407, 2011
12. for dan C.T., Guzman ML, Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006 (Pubitemid 44427449)
13. Kang MK, Hur BI, Ko M.H., Kim CH, Cha SH, Kang SK: Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci 9: 15, 2008
14. Keunen O, Johansson M, Oudin A., Sanzey M, Rahim SA, Fack F, et al.: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108: 3749-3754, 2011
15. Kleihues P, Burger PC, Collins V.P., Newcomb EW, Ohgaki H, Cavenee WK: Glioblastoma, in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumors of the Nervous System, ed 2. Lyon: IARC Press, 2000, pp 29-39
16. Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1: 44-51, 1999
17. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J: Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 86: 31-45, 2008 (Pubitemid 350263430)
18. Miraglia S, Godfrey W, Yin A.H., Atkins K., Warnke R, Holden JT, et al.: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021, 1997 (Pubitemid 28007218)
19. Nandi S, Ulasov IV, Tyler M.A., Sugihara AQ, Molinero L, Han Y, et al.: Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 68: 5778-5784, 2008
20. Ogden AT, Waziri AE, Lochhead R.A., Fusco D., Lopez K, Ellis JA, et al.: Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 62: 505-515, 2008
21. Pàez-Ribes M., Allen E, Hudock J., Takeda T, Okuyama H, Viñals F, et al.: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009
22. Pallini R, Ricci-Vitiani L, Banna G.L., Signore M., Lombardi D, Todaro M, et al.: Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14: 8205-8212, 2008
23. Phillips TM, McBride WH, Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785, 2006 (Pubitemid 46017929)
24. Reya T, Morrison SJ, Clarke M.F., Weissman IL Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001 (Pubitemid 33041634)
25. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G: Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120: 567-584, 2010
26. Sakariassen PO, Prestegarden L, Wang J., Skaftnesmo KO, Mahesparan R, Molthoff C, et al.: Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A 103: 16466-16471, 2006 (Pubitemid 44715219)
27. Singh SK, Clarke ID, Terasaki M, Bonn V.E., Hawkins C., Squire J, et al.: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003 (Pubitemid 37187480)
28. Singh SK, Hawkins C, Clarke I.D., Squire JA, Bayani J, Hide T, et al.: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004 (Pubitemid 39551674)
29. Son MJ, Woolard K, Nam D.H., Lee J., Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4: 440-452, 2009
30. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005 (Pubitemid 40349501)
31. Tamura K, Aoyagi M, Wakimoto H., Ando N, Nariai T, Yamamoto M., et al.: Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. Clinical article. J Neurosurg 113: 310-318, 2010
32. Vlashi E, Kim K, Lagadec C., Donna LD, McDonald JT, Eghbali M, et al.: In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101: 350-359, 2009
33. Wakimoto H, Aoyagi M, Nakayama T., Nagashima G, Yamamoto S, Tamaki M., et al.: Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77: 373-380, 1996 (Pubitemid 26025528)
34. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008
35. Zeppernick F, Ahmadi R, Campos B., Dictus C, Helmke BM, Becker N, et al.: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129, 2008 (Pubitemid 351377986)